Dr. Bastholt on Lenvatinib in NSCLC

Lars Bastholt, MD
Published: Friday, Oct 07, 2016



Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses the use of lenvatinib to treat patients with non-small cell lung cancer (NSCLC) at the 2016 ESMO Congress.

A phase II study of the agent demonstrated promising clinical activity in a small subset of patients with NSCLC. Approximately 40% of these patients have adenocarcinoma of the lung, and 1% to 2% of those patients have a RET mutation. It is in this specific setting, Bastholt explains, that lenvatinib has demonstrated significant outcomes.

Despite some manageable toxicities associated with this agent, these efficacious results provide support for further study of lenvatinib for RET-positive adenocarcinoma of the lung.


Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses the use of lenvatinib to treat patients with non-small cell lung cancer (NSCLC) at the 2016 ESMO Congress.

A phase II study of the agent demonstrated promising clinical activity in a small subset of patients with NSCLC. Approximately 40% of these patients have adenocarcinoma of the lung, and 1% to 2% of those patients have a RET mutation. It is in this specific setting, Bastholt explains, that lenvatinib has demonstrated significant outcomes.

Despite some manageable toxicities associated with this agent, these efficacious results provide support for further study of lenvatinib for RET-positive adenocarcinoma of the lung.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x